Tag Archives: Iterum Therapeutics Plc

August 15, 2019   No comments

H.C. Wainwright Remains a Buy on Iterum Therapeutics Plc (ITRM)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Iterum Therapeutics Plc (ITRM – Research Report) today and set a price target of $17. The company’s shares closed last Monday at $6.81. According to TipRanks.com, Arce is a 4-star

Read More
June 21, 2019   No comments

H.C. Wainwright Initiates a Buy Rating on Iterum Therapeutics Plc (ITRM)

In a report released today, Ed Arce from H.C. Wainwright initiated coverage with a Buy rating on Iterum Therapeutics Plc (ITRM – Research Report) and a price target of $17. The company’s shares closed yesterday at $6.60. Arce commented: “Valuation

Read More
March 25, 2019   No comments

Needham Sticks to Its Buy Rating for Iterum Therapeutics Plc (ITRM)

Needham analyst Alan Carr maintained a Buy rating on Iterum Therapeutics Plc (ITRM – Research Report) today and set a price target of $20. The company’s shares opened today at $7.02. Carr said: “Iterum reported 4Q18 financial results today. Mgmt

Read More